Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21542/gcsp.2018.2 http://scihub22266oqcxt.onion/10.21542/gcsp.2018.2 C5857062!5857062!29644229     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Glob+Cardiol+Sci+Pract ä ; 2018 (1): ä Nephropedia Template TP {{tp|p=29644229|t=ä. CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis |pdf=|usr=}}{{29644229}} gab.com Text CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis JO: Glob Cardiol Sci Pract http://www.kidney.de/pget.php?&tw=1&pmid=29644229 #FOAvip Atherosclerosis is no longer considered solely a disorder of subintimal deposition of modified low-density lipoprotein particles in the arterial wall. Rather, it is known to be a chronic inflammatory disorder. No evidence has shown that reducing vascular inflammation in the absence of concomitant lowering of lipoproteins levels reduces the rates of adverse cardiovascular (CV) events. Canakinumab, a fully human monoclonal antibody that neutralizes interleukin (IL)-1?, significantly reduced the rate of recurrent CV events in patients with prior myocardial infarction in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS). Canakinumab has no effect on CV or all-cause mortality, however it was associated with high incidence of fatal infections. Thus, the net benefit needs to be properly addressed in future studies that evaluate the potential benefit of the anti-inflammatory therapies and whether it can change clinical practice in the near future. Twit Text FOAVip CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis ????Glob Cardiol Sci Pract http://www.kidney.de/pget.php?&tw=1&pmid=29644229 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29644229 #FOAvip English Wikipedia <ref>{{Cite pmid|29644229}}</ref> CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis #MMPMID29644229 Hassan M Glob Cardiol Sci Pract ä[]; 2018 (1): ä PMID29644229show ga Atherosclerosis is no longer considered solely a disorder of subintimal deposition of modified low-density lipoprotein particles in the arterial wall. Rather, it is known to be a chronic inflammatory disorder. No evidence has shown that reducing vascular inflammation in the absence of concomitant lowering of lipoproteins levels reduces the rates of adverse cardiovascular (CV) events. Canakinumab, a fully human monoclonal antibody that neutralizes interleukin (IL)-1?, significantly reduced the rate of recurrent CV events in patients with prior myocardial infarction in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS). Canakinumab has no effect on CV or all-cause mortality, however it was associated with high incidence of fatal infections. Thus, the net benefit needs to be properly addressed in future studies that evaluate the potential benefit of the anti-inflammatory therapies and whether it can change clinical practice in the near future. äCANTOS: A breakthrough that proves the inflammatory hypothesis of athe(epmc).pdf DeepDyve Pubget Overpricing